Fresenius Medical Care Corporation (FMS) Stock Rating Upgraded by Zacks Investment Research

Fresenius Medical Care Corporation (NYSE:FMS) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a research report issued on Monday.

According to Zacks, “Fresenius Medical Care has had a disappointing run on the bourse on a year-to-date basis. The company  ended the second quarter on a mixed note wherein adjusted earnings missed the Zacks Consensus Estimate, while revenues beat the same. Fresenius Medical Care reiterated its full-year guidance. We believe this is in tune with the company’s long-term objective or the ‘Growth Strategy 2020’, wherein it aims to drive revenues to $28 billion by 2020, corresponding to an average annual growth rate of 10%. A wide range of dialysis products, initiatives to attain market traction, solid international foothold, strategic acquisitions and divestments are major catalysts. Fresenius Medical Care has signed an agreement to acquire NxStage Medical for $2 billion. However, a tough regulatory environment, difficulties in boosting the profit margin in foreign legal paradigms and competition in the niche markets are major headwinds.”

Other analysts have also issued reports about the stock. Royal Bank Of Canada reaffirmed a “hold” rating and set a $44.00 price target on shares of Fresenius Medical Care Corporation in a research report on Wednesday, September 13th. UBS AG reaffirmed a “sell” rating on shares of Fresenius Medical Care Corporation in a research report on Tuesday, July 4th. BidaskClub lowered shares of Fresenius Medical Care Corporation from a “buy” rating to a “hold” rating in a research report on Monday, July 31st. DZ Bank AG reaffirmed a “buy” rating on shares of Fresenius Medical Care Corporation in a research report on Monday, August 7th. Finally, Nord/LB reaffirmed a “buy” rating on shares of Fresenius Medical Care Corporation in a research report on Wednesday, June 28th. One equities research analyst has rated the stock with a sell rating, five have assigned a hold rating and six have assigned a buy rating to the company’s stock. The stock currently has a consensus rating of “Hold” and a consensus price target of $48.67.

Fresenius Medical Care Corporation (FMS) opened at 47.74 on Monday. The company has a 50-day moving average of $48.13 and a 200 day moving average of $46.74. The company has a market cap of $29.30 billion, a P/E ratio of 20.49 and a beta of 0.48. Fresenius Medical Care Corporation has a one year low of $38.05 and a one year high of $50.22.

Fresenius Medical Care Corporation (NYSE:FMS) last posted its quarterly earnings results on Tuesday, August 1st. The company reported $0.48 earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of $0.53 by ($0.05). Fresenius Medical Care Corporation had a return on equity of 11.57% and a net margin of 7.06%. The firm had revenue of $4.47 billion for the quarter, compared to the consensus estimate of $5.20 billion. During the same period last year, the company posted $0.96 earnings per share. The business’s revenue was up 11.1% compared to the same quarter last year. Equities research analysts predict that Fresenius Medical Care Corporation will post $2.34 EPS for the current year.

WARNING: “Fresenius Medical Care Corporation (FMS) Stock Rating Upgraded by Zacks Investment Research” was originally published by StockNewsTimes and is the sole property of of StockNewsTimes. If you are reading this report on another publication, it was copied illegally and republished in violation of United States and international trademark and copyright laws. The legal version of this report can be viewed at https://stocknewstimes.com/2017/10/11/fresenius-medical-care-corporation-fms-stock-rating-upgraded-by-zacks-investment-research.html.

Several institutional investors and hedge funds have recently modified their holdings of the company. Level Four Advisory Services LLC raised its position in shares of Fresenius Medical Care Corporation by 0.5% in the first quarter. Level Four Advisory Services LLC now owns 11,434 shares of the company’s stock valued at $478,000 after purchasing an additional 58 shares during the period. UBS Asset Management Americas Inc. raised its position in shares of Fresenius Medical Care Corporation by 3.6% in the second quarter. UBS Asset Management Americas Inc. now owns 2,357 shares of the company’s stock valued at $114,000 after purchasing an additional 81 shares during the period. Greenleaf Trust raised its position in shares of Fresenius Medical Care Corporation by 2.6% in the second quarter. Greenleaf Trust now owns 4,992 shares of the company’s stock valued at $241,000 after purchasing an additional 126 shares during the period. Sawtooth Solutions LLC raised its position in shares of Fresenius Medical Care Corporation by 2.9% in the second quarter. Sawtooth Solutions LLC now owns 4,887 shares of the company’s stock valued at $236,000 after purchasing an additional 137 shares during the period. Finally, Wrapmanager Inc. raised its position in shares of Fresenius Medical Care Corporation by 2.4% in the second quarter. Wrapmanager Inc. now owns 7,392 shares of the company’s stock valued at $357,000 after purchasing an additional 170 shares during the period. 2.61% of the stock is currently owned by institutional investors.

Fresenius Medical Care Corporation Company Profile

Fresenius Medical Care AG & Co KGaA is a kidney dialysis company. The Company provides dialysis care and related services to persons suffering from end-stage renal disease (ESRD), as well as other healthcare services. The Company’s segments include North America Segment, the Europe, Middle East and Africa (EMEA) Segment, the Asia-Pacific Segment and the Latin America Segment.

Analyst Recommendations for Fresenius Medical Care Corporation (NYSE:FMS)

Receive News & Ratings for Fresenius Medical Care Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fresenius Medical Care Corporation and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply